About Oralair(R) Grasses
Oralair(R) Grasses is a tablet for desensitization to grass pollens, the allergen that causes rhinoconjunctivitis and allergic rhinitis in more than 50% of patients in Europe.
With a safe and easy-to-use daily tablet of Oralair(R) Grasses, patients enjoy a very significant alleviation of all their rhinoconjunctivitis symptoms, a marked reduction in their symptomatic medication use and a noticeable improvement in their quality of life.
Oralair(R) Grasses has been shown to be effective in rhinoconjunctivitis caused by allergy to grass pollens from the first season, throughout the entire pollen season and during pollen peaks:
- in poly- and mono-sensitized patients and asthmatic patients, - on every individual symptom, and, in particular, on nasal congestion and watery eyes.
Oralair(R) Grasses is indicated as a pre- and coseasonal treatment: treatment should be started four months before the pollen season starts and then be maintained throughout the season. Treatment should be repeated, following the same protocol, for 3 consecutive pollen seasons.
Oralair(R) Grasses contains a mix of five standardized grass pollens, mimicking patients' natural exposure: perennial rye grass (Lolium perenne), meadow grass (Poa pratensis), timothy grass (Phleum pratense), cocksfoot (Dactylis glomerata) and sweet vernal grass (Anthoxanthum odoratum).
The clinical development program has already enrolled around 1,600
patients to date, including 278 children. A pivotal trial aimed at confirming
the long-term efficacy of the treatment is currently under way. In line with
the program schedule, the results will be communicated at the end of 2009.
Finally, the company is presently carrying out a trial in adults, with a view
Copyright©2009 PR Newswire.
All rights reserved